| Vol. 13.27 – 18 November, 2022 |
| |
|
|
| Researchers showed that increasing prostatic stromal Foxf2 suppressed the growth and progression of both syngeneic and autochthonous mouse prostate cancer models in an immunocompetent context. [Nature Communications] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators uncovered a mechanism of alternative polyadenylation regulation impinging on the interaction between the exonuclease XRN2 and the RNA-binding protein Sam68, whose increased expression in prostate cancer was promoted by the transcription factor MYC. [Nature Structural & Molecular Biology] |
|
|
|
| Using the Canadian Prostate Cancer Biomarker Network biobank, scientists analyzed UGT2B28 tumor expression in relation to clinical outcomes in men with localized prostate cancer. [Cancer Letters] |
|
|
|
| The authors found that SR9009 was specifically lethal to prostate cancer (PCa) cell lines but had no cytotoxic effect on prostate cells. SR9009 significantly inhibited colony formation, the cell cycle, and cell migration and promoted apoptosis in PCa cells. [Cell Death & Disease] |
|
|
|
| Through analysis of RNA-seq data, researchers nominated ARHGEF2 as a pivotal androgen-repressed gene. They showed that ARHGEF2 was directly suppressed by androgen/androgen receptor. [Cell Death & Disease] |
|
|
|
| The systemic metabolic consequences of UGT deficiencies were examined using untargeted and targeted mass spectrometry-based metabolomics profiling of carefully matched, treatment-naive prostate cancer cases. [British Journal of Cancer] |
|
|
|
| Scientists studied AGAP2 expression in prostate cancer and chronic myeloid leukemia, showing transcription was initiated from alternative transcription start sites (TSSs) within a single TSS cluster, producing cancer-type-specific AGAP2 mRNAs with small differences in their 5′ UTR length. [iScience] |
|
|
|
| Investigators performed bioinformatic analysis and immunohistochemical staining on normal and cancerous prostate tissue to evaluate ERα and NRF2 expression and their correlation. [Cell Communication and Signaling] |
|
|
|
| Researchers uncovered the biological roles of deubiquitylase USP35 in prostate adenocarcinoma and found effective epigenetic or metabolic targets. [Cell Death Discovery] |
|
|
|
| Scientists showed a novel pathway activated by αVβ3 that promoted neuroendocrine differentiation in prostate cancer. This novel pathway required the expression of a glycosylphosphatidylinositol-linked surface molecule, NgR2, also known as Nogo-66 receptor homolog 1. [Scientific Reports] |
| |
|
|
|
| The authors overview the current evidence on the pathological androgen milieu by altered metabolism and transport in prostate cancer, leading to resistance to endocrine therapy. [Urologic Oncology-Seminars and Original investigations] |
|
|
|
| Investigators analyze the current literature regarding the role of natural and synthetic compounds in modulating nuclear factor erythroid 2-related factor 2 (NRF2) pathway in transgenic adenocarcinoma of mouse prostate (TRAMP) mice, an in vivo model of prostate cancer. [Molecular Biology Reports] |
|
|
|
|
| AstraZeneca and MSD’s Lynparza in combination with abiraterone and prednisone or prednisolone has been recommended for marketing authorization in the European Union for the treatment of adult patients with mCRPC for whom chemotherapy is not clinically indicated. [AstraZeneca] |
|
|
|
|
| April 23 – 28, 2023 Cancun, Mexico |
|
|
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Columbia University in the City of New York – New York, New York, United States |
|
|
|
| STEMCELL Technologies, Inc. – Boston, Massachusetts, United States |
|
|
|
| Imperial College London – London, England, United Kingdom |
|
|
|
| University of Illinois Chicago – Chicago, Illinois, United States |
|
|
|
|